CLAIMS

1. Use of an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising a eukaryotic expression cassette encoding VEGFR-2 in the manufacture of a medicament for cancer immunotherapy, wherein the cancer is characterized by VEGFR-2 expressing cancer cells, and wherein the attenuated strain of Salmonella is Salmonella typhi Ty21a.

2. The use according to claim 1, wherein the cancer is selected from the group consisting of glioblastoma, carcinoid cancer, kidney cancer, particularly renal cell carcinoma, thyroid cancer, lung cancer, particularly Non-Small Cell Lung Cancer (NSCLC), breast cancer, ovarian cancer, prostate cancer, gastrointestinal cancer, particularly colorectal cancer, more particularly colon cancer, and skin cancer, particularly melanoma.

3. Use of an attenuated strain of Salmonella comprising at least one copy of a DNA molecule comprising a eukaryotic expression cassette encoding VEGFR-2in the manufacture of a medicament for cancer immunotherapy in a patient comprising at least one VEGFR-2 expressing cancer cell.

4. The use according to any one of claims 1 to 3, wherein the expression cassette comprises a CMV promoter.

5. The use according to any one of claims 1 to 4, wherein the VEGF receptor protein selected from the group consisting of VEGFR-2 having the amino acid sequence as found in SEQ ID NO 1 and a protein that shares at least 80% sequence identity therewith, particularly wherein the VEGFR-2 has the amino acid sequence as found in SEQ ID NO 1.

6. The use according to any one of claims 1 to 5, wherein the DNA molecule comprises the kanamycin antibiotic resistance gene, the pMB1 ori and a CMV promoter, particularly wherein the DNA molecule comprises the DNA sequence as found in SEQ ID NO 2.

7. The use according to any one of claims 1 to 6, wherein cancer immunotherapy is accompanied by chemotherapy, radiotherapy or biological cancer therapy, particularly wherein the attenuated strain of Salmonella is to be administered before, during or after the chemotherapy or the radiotherapy treatment or the biological cancer therapy, or before and during the chemotherapy or the radiotherapy treatment or the biological cancer therapy.

8. The use according to claim 7, wherein the biological cancer therapy comprises at least one further DNA vaccine encoding a tumor antigen and/or a tumor stroma antigen to be administered, particularly selected from at least one further attenuated strain of Salmonella comprising at least one copy of a further DNA molecule comprising a further expression cassette encoding a tumor antigen and/or a tumor stroma antigen, particularly wherein said at least one further attenuated strain of Salmonella is Salmonella typhi Ty21a comprising a further eukaryotic expression cassette.

9. The use according to claim 8, wherein said tumor antigen encoded by said at least one further DNA vaccine is selected from the group consisting of human Wilms' Tumor Protein (WT1), human Mesothelin (MSLN), human CEA and CMV pp65.

10. The use according to claim 9, wherein said tumor antigen is selected from the group consisting of human Wilms' Tumor Protein (WT1) having the amino acid sequence as found in SEQ ID NO 3 and a protein that shares at least about 80% sequence identity therewith, human Mesothelin (MSLN) having the amino acid sequence as found in SEQ ID NO 4 and a protein that shares at least

about 80% sequence identity therewith, human CEA having the amino acid sequence as found in SEQ ID NO 5 and a protein that shares at least about 80% sequence identity therewith, CMV pp65 having the amino acid sequence as found in SEQ ID NO 6 and a protein that shares at least about 80% sequence identity therewith, CMV pp65 having the amino acid sequence as found in SEQ ID NO 7 and a protein that shares at least about 80% sequence identity therewith, and CMV pp65 having the amino acid sequence as found in SEQ ID NO 8 and a protein that shares at least about 80% sequence identity therewith.

11. The use according to claim 8, wherein said tumor stroma antigen encoded by said at least one further DNA vaccine is human fibroblast activation protein (FAP).

12. The use according to any one of claims 1 to 11, wherein the attenuated strain of Salmonella is to be administered orally.

13. The use according to any one of claims 1 to 12, wherein the single dose of the attenuated strain of Salmonella comprises from about 10^5 to about 10^{11}, particularly from about 10^6 to about 10^{10}, more particularly from about 10^6 to about 10^9, more particularly from about 10^6 to about 10^8, most particularly from about 10^6 to about 10^7 colony forming units (CFU).

14. The use according to any one of claims 1 to 13, wherein it is for individualized cancer immunotherapy comprising the step of assessing the expression pattern of and/or the pre-immune response against VEGFR-2 in a patient.